These included: Sodium-Glucose Transporter 2 inhibitors, SGLT2 inhibitors, Canagliflozin, Dapagliflozin, Empagliflozin, Sotagliflozin, Ipragliflozin, Ertugliflozin, Heart Failure, SGLT2 inhibitors AND Heart Failure, Canagliflozin OR Empagliflozin AND Heart Failure, SGLT2 inhibitors AND Cardiovascular Outcome OR Hospitalization Rates OR Quality of Life, as well as the Effectiveness of SGLT2 inhibitors on Quality of Life. Here, SLC5A2 is linked to heart failure.